Trial Profile
Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Therapeutic Use
- Acronyms PrEP Brasil
- 27 Jul 2018 Results evaluating self-reported PrEP adherence and its perceived barriers and facilitators among men who have sex with men and trans-gender women retained though 48 weeks (n=375) presented at the 22nd International AIDS Conference
- 27 Jul 2018 Results assessing the measures of adherence to HIV pre-exposure prophylaxis (PrEP) among men who have sex with men and trans-gender women (n=354) presented at the 22nd International AIDS Conference
- 29 Aug 2017 New trial record